

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.*



*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1477)**

## **COMPLETION OF ISSUE OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE**

Reference is made to the announcement of Ocumension Therapeutics (the “**Company**”) dated April 14, 2021 and the circular of the Company dated May 28, 2021 (the “**Circular**”), in relation to, among other things, the issue of Warrants under the Specific Mandate. Terms used in this announcement shall have the same meanings as defined in the Circular unless otherwise stated.

### **COMPLETION OF THE ISSUE OF WARRANTS**

The Board is pleased to announce that all conditions precedent under the Warrant Subscription Agreement have been fulfilled and the completion of the issue of Warrants took place on August 13, 2021 in accordance with the terms and conditions of the Warrant Subscription Agreement. Upon completion, the Company issued the Warrants at a nominal consideration of HK\$1.00 to Alimera, conferring it rights to subscribe for an aggregate of 1,000,000 Warrant Shares at the subscription price of HK\$23.88 for each Warrant Share during the period of 48 months commencing from the date of issue of the Warrants.

### **EFFECT ON THE SHAREHOLDING STRUCTURE**

Assuming that there will be no further changes in the issued share capital of the Company prior to the exercise of the subscription rights attaching to the Warrants, upon full exercise of the subscription rights attaching to the Warrants, a total of 1,000,000 Warrant Shares will be allotted and issued, representing (i) approximately 0.1584% of the existing issued Shares as of the date of this announcement; and (ii) approximately 0.1582% of the total number of 632,205,380 Shares in issue as enlarged by the allotment and issue of the Warrant Shares. Assuming 1,000,000 Warrant Shares are issued, an aggregate amount of subscription monies of approximately HK\$23.88 million will be raised.

As of the date of this announcement, the Company has a total of 631,205,380 Shares in issue. The shareholding structure of the Company (i) as of the date of this announcement; and (ii) upon the subscription of the Warrants and full exercise of the subscription rights attaching to the Warrants, are expected to be as follows (assuming there are no other changes to the issued share capital of the Company and for illustration purpose only):

	<b>As of the date of this announcement</b>		<b>Immediately after the exercise of the Warrants at the initial subscription price in full</b>	
	<i>No. of Shares</i>	<i>%</i>	<i>No. of Shares</i>	<i>%</i>
<b>Existing Shareholders</b>	631,205,380	100%	631,205,380	99.8418%
<b>Alimera</b>	0	0	1,000,000	0.1582%
<b>Total</b>	<b>631,205,380</b>	<b>100%</b>	<b>632,205,380</b>	<b>100%</b>

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, August 13, 2021

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive Directors.*